Enhancing Growth Inhibition of Prostate Cancer Cells
Author Information
Author(s): MJ Campbell, M Dawson, HP Koeffler
Primary Institution: Cedars-Sinai Medical Center/UCLA School of Medicine
Hypothesis
In hormonally insensitive prostate cancer cells, Bcl-2 may play another role in promoting cell growth, and its inhibition combined with retinoids could provide a novel therapeutic approach.
Conclusion
The combination of Bcl-2 antisense oligonucleotides and the synthetic retinoid 2-HPR significantly inhibited the growth of DU-145 prostate cancer cells without inducing apoptosis.
Supporting Evidence
- Cell growth was significantly inhibited by antisense Bcl-2 oligonucleotides compared with control.
- Inhibition was significantly enhanced when combined with the synthetic retinoid 2-HPR.
- Treatment with antisense oligonucleotides resulted in a 46% reduction in Bcl-2 protein expression.
Takeaway
Researchers found that a special treatment can slow down the growth of prostate cancer cells, but it doesn't make the cells die like they expected.
Methodology
The study used DU-145 prostate cancer cells and tested the effects of antisense Bcl-2 oligonucleotides alone and in combination with retinoids on cell growth and apoptosis.
Limitations
The study did not demonstrate increased apoptosis despite significant growth inhibition.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website